BioWorld3h
US FDA clears Cobenfy, first new schizophrenia drug in decades
The FDA has approved Cobenfy, a dual M1/M4 muscarinic agonist that offers a fundamentally different approach to treating ...
Des Moines Register5h
This FDA-approved drug promises a new way to treat schizophrenia
The promising drug combination was discovered and tested by Karuna Therapeutics, which Bristol Myers Squibb acquired in March. Bristol Myers Squibb will sell the drug combination under the brand name ...
WFDD5h
A new kind of drug for schizophrenia promises fewer side effects
A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...
GlobalData on MSN6h
BMS wins approval for schizophrenia drug acquired from Karuna
The FDA has approved the first treatment for schizophrenia that targets cholinergic receptors rather than dopamine receptors.
btimesonline8h
FDA Approves Bristol Myers Squibb’s Cobenfy, First Novel Schizophrenia Drug in 70 Years
Bristol Myers Squibb received U.S. Food and Drug Administration (FDA) approval on Thursday for its groundbreaking ...
Bristol-Myers Squibb: Cobenfy Approval A Major Coup For The Dealmaker (Upgrade)
Bristol-Myers Squibb's acquisition of Karuna and FDA approval of Cobenfy signal growth potential, with focus on driving ...
FDA Approves New Schizophrenia Drug in 70-Year First
The treatment offers hope to thousands of patients who do not respond to existing medications, and has shown promise in treating other neurological disorders.
Cancer Research2d
About the Journal
Molecular Cancer Therapeutics publishes articles on the discovery and preclinical development of novel therapeutic agents for oncology, preclinical studies of approved therapeutics, mechanisms of drug ...